(480) 821-2838


(QOPI) Certification program, an affiliate of the American Society of Clinical Oncology - Learn More

Open Trials

Breast Cancer Trials:

Previously treated metastatic HER2+Breast Cancer

Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast Cancer (SOPHIA)
New sub-study includes margetuximab plus chemotherapy with decreased infusion time.
https://clinicaltrials.gov/ct2/show/NCT02492711?term=CP-MGAH22-04&rank=1
For questions, please contact 480-398-7671.

 

Lung Cancer Trials:

2nd or 3rd line treatment for Non-Small Cell Lung Cancer (NSCLC) after prior Platinum-Based Chemotherapy

Assessment of Docetaxel + Plinabulin Compared to Docetaxel + Placebo in Patients With Advanced NSCLC With at Least One Measurable Lung Lesion (DUBLIN-3)
https://clinicaltrials.gov/ct2/show/NCT02504489
For questions please contact 480-398-7671.

 

Previously treated small cell lung cancer (SCLC)

Clinical Trial of Lurbinectedin (PM01183)/Doxorubicin (DOX) Versus Cyclophosphamide (CTX), Doxorubicin (DOX) and Vincristine (VCR) (CAV) or Topotecan as Treatment in Patients With Small-Cell Lung Cancer (ATLANTIS)
https://clinicaltrials.gov/ct2/show/NCT02566993?term=PM1183-C-003-14&rank=1

For questions, please contact 480-398-7671.

 

Lymphoma Trials:

Previously treated Non-Hodgkin’s Lymphoma (Follicular, Small Lymphocytic Leukemia, Marginal Zone, Diffuse Large B-Cell Lymphoma)

https://clinicaltrials.gov/ct2/show/NCT02793583?term=UTX-TGR-205&rank=1

For questions please contact 480-398-7671.

 

Melanoma Trials:

Maintenance Treatment for Patients with Resected Stage IIB, IIC, or III Melanoma

A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence.
https://clinicaltrials.gov/ct2/show/NCT01546571?term=103A-301&rank=1
For questions, please contact 480-398-7671.
*ENROLLMENT IS CURRENTLY ON HOLD FOR THIS TRIAL**

 

Prostate Cancer Trials:

Metastatic castration-resistant prostate cancer with no prior treatment

Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer (IPATential150)
https://clinicaltrials.gov/ct2/show/NCT03072238?term=CO39303&rank=1
For questions please contact 480-398-7671.

 

Localized or locally advanced Prostate Cancer receiving radiation

An Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS
https://clinicaltrials.gov/ct2/show/NCT02531516?term=56021927PCR3003&rank=1
For questions please contact 480-398-7671.

 

Urothelial Cancer Trials:

Advanced or metastatic urothelial carcinoma of the renal pelvis, uterer, bladder, or urethra

Phase III Randomized Controlled Trial of Pembrolizumab with or without Chemo vs Chemo in Advanced Urothelial Carcinoma
https://clinicaltrials.gov/ct2/show/NCT02853305?term=KEYNOTE-361&rank=1
For questions, please contact 480-398-7671.